A perspective of Mycobacterium Tuberculosis resistance on patients with retreat in Madagascar

Harison Michel Tiaray, K. Ravahatra, J. Rajaoarifetra, O. F. Rakotondrasoa, Iantsotiana Davidson Rakotondrabe, Marie odette Rasoafaranirina Anjara Mihaja Nandimbiniaina, J. Rakotomizao, Rakotoson Joëlson Lovaniaina, Andrianasolo Radonirina Lazasoa, Raharimanana Rondro Nirina
{"title":"A perspective of Mycobacterium Tuberculosis resistance on patients with retreat in Madagascar","authors":"Harison Michel Tiaray, K. Ravahatra, J. Rajaoarifetra, O. F. Rakotondrasoa, Iantsotiana Davidson Rakotondrabe, Marie odette Rasoafaranirina Anjara Mihaja Nandimbiniaina, J. Rakotomizao, Rakotoson Joëlson Lovaniaina, Andrianasolo Radonirina Lazasoa, Raharimanana Rondro Nirina","doi":"10.15520/IJMHS.V10I03.2828","DOIUrl":null,"url":null,"abstract":"Introduction: Despite advances in diagnostic and therapeutic way, drug-resistanttuberculosis is an increasingly worrying threat. Several studies suggest that one ofthe risk factors for carrying resistant Mycobacterium tuberculosis is the historyof anti-tuberculosis treatment. The objective of our study is to describe theResistance Profile of Mycobacterium Tuberculosis of patients in retreatment inMadagascar. Methods: This is a descriptive and retrospective study, carried outfrom January 2014 to September 2018 (45 months). All the cases of re-treatementrecorded in the database of the National Tuberculosis Control Program inMadagascar were included in the study.Results: We gathered 1456 cases, the average age was 40 years, there was a malepredominance(sex ratio of 2.32). In the 1302 cases where the category wasspecified, there was a predominance of relapse (76.57%). According to theculture, the incidence of rifampicin resistance was 05.36% (78/1456) including83.33% of cases of multi-resistant tuberculosis (MDR-TB) (65/78). The incidenceof isoniazid monoresistance was 05.49% (80/1456). Carrying MDR-TB is much moreimportant for patients who have failed (69.43%). The GeneXpert mtb/RIF enabledus to detect more cases of Rifampicine monoresistance (97 cases).Conclusion: cases of retreatment is a real source of the emergence of MDR-TB inMadagascar, especially cases of failure and relapse. Which is consistent with the data inthe literature. The treatment effectiveness of new cases must be maximum to preventthese cases of retreatment.Key words: drug resistance–Madagascar–profil–tuberculosis","PeriodicalId":13590,"journal":{"name":"Innovative Journal of Medical and Health Science","volume":"386 1","pages":"835-838"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovative Journal of Medical and Health Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15520/IJMHS.V10I03.2828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Despite advances in diagnostic and therapeutic way, drug-resistanttuberculosis is an increasingly worrying threat. Several studies suggest that one ofthe risk factors for carrying resistant Mycobacterium tuberculosis is the historyof anti-tuberculosis treatment. The objective of our study is to describe theResistance Profile of Mycobacterium Tuberculosis of patients in retreatment inMadagascar. Methods: This is a descriptive and retrospective study, carried outfrom January 2014 to September 2018 (45 months). All the cases of re-treatementrecorded in the database of the National Tuberculosis Control Program inMadagascar were included in the study.Results: We gathered 1456 cases, the average age was 40 years, there was a malepredominance(sex ratio of 2.32). In the 1302 cases where the category wasspecified, there was a predominance of relapse (76.57%). According to theculture, the incidence of rifampicin resistance was 05.36% (78/1456) including83.33% of cases of multi-resistant tuberculosis (MDR-TB) (65/78). The incidenceof isoniazid monoresistance was 05.49% (80/1456). Carrying MDR-TB is much moreimportant for patients who have failed (69.43%). The GeneXpert mtb/RIF enabledus to detect more cases of Rifampicine monoresistance (97 cases).Conclusion: cases of retreatment is a real source of the emergence of MDR-TB inMadagascar, especially cases of failure and relapse. Which is consistent with the data inthe literature. The treatment effectiveness of new cases must be maximum to preventthese cases of retreatment.Key words: drug resistance–Madagascar–profil–tuberculosis
马达加斯加撤退患者结核分枝杆菌耐药性的观察
导言:尽管诊断和治疗手段取得了进步,但耐药结核病的威胁日益令人担忧。一些研究表明,携带耐药结核分枝杆菌的危险因素之一是抗结核治疗史。本研究的目的是描述马达加斯加再治疗结核分枝杆菌患者的耐药情况。方法:2014年1月至2018年9月(45个月)进行描述性回顾性研究。马达加斯加国家结核病控制规划数据库中记录的所有再治疗病例均纳入研究。结果:共收集病例1456例,平均年龄40岁,男性占优势,性别比为2.32。在1302例明确分类的病例中,复发率最高(76.57%)。培养结果显示,利福平耐药发生率为05.36%(78/1456),其中耐多药结核病(MDR-TB)占83.33%(65/78)。异烟肼单药耐药率为05.49%(80/1456)。对于治疗失败的患者,携带耐多药结核病更为重要(69.43%)。GeneXpert mtb/RIF使我们能够发现更多的利福平单药耐药病例(97例)。结论:再治疗病例是马达加斯加出现耐多药结核病的真正根源,特别是治疗失败和复发病例。这与文献中的数据一致。必须最大限度地提高新病例的治疗效果,以防止这些病例的再治疗。关键词:耐药-马达加斯加-结核
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信